Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Michael Whitfield
Dartmouth College, Department: Other Basic Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Celdara Medical, LLC
Other : Intellectual Property: Income from Intellectual Property license (royalties from awardee institution)
There is the potential for the value of certain technology which has been developed in Dr. Whitfield’s lab at Dartmouth (and is now licensed to Celdara Medical, LLC) to be affected by the outcome of this work. Dr. Whitfield further has a financial interest in Celdara Medical, which has developed and markets products and services based on the licensed technology. In light of Dr. Whitfield’s role as the PI and his interest in the aforementioned intellectual property and financial interest the company seeking to commercialize this IP, the Dartmouth Conflict of Interest Committee considers this to meet the criteria of an FCOI as having the potential for a direct and significant impact on the design, conduct and/or reporting of the research project.
Molecular biomarkers of improvement for patients with systemic sclerosis in an open label trial of mycophenolate mofetil
Systemic sclerosis or scleroderma (SSc) is an autoimmune disease of unknown etiology that is characterized by vascular dysfunction, fibrosis, and inflammation. We have identified four reproducible gene expression subsets of disease by using genomic methodologies in three independent patient cohorts. We find that these groups are not distinguishable by any standard of care clinical measures. This pilot and clinical feasibility research grant proposal will incorporate genome-wide analysis of the expressed genes to predict which patients will improve while on MMF therapy. These data will be analyzed and patients assigned to subset using our computationally defined and tested analytic algorithm for assigning individual patients to intrinsic gene expression subset. These data will be couple with measurement of serum biomarkers to identify circulating factors that predict changes in modified Rodnan Skin Score (MRSS), the most commonly used outcome measure in SSc clinical trials. These data will be collected on patients in an ongoing clinical trial of MMF at Northwestern's Feinberg School of Medicine with additional samples coming from Stanford, University of Michigan and Johns Hopkins. The result will be biomarkers that will predict which patients improve while on MMF therapy and molecular measures in the form of genes or serum biomarkers that objectively measure response. Ultimately this same paradigm will be applicable to any clinical trial in SSc.
Filed on June 05, 2015.
Tell us what you know about Michael Whitfield's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Michael Whitfield filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Michael Whitfield | Dartmouth College | Conflict of Interest | Celdara Medical, LLC | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.